Skip to main content

Table 6 Baseline characteristics and VAP episode description in the statin previous users according to the 30-day mortality

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

 

Survivors

Nonsurvivors

P

(n = 60)

(n = 33)

Age (years)

62.5 (27.0-81.0)

74.0 (50.0-90.0)

<0.01

SAPS II (points)

48.0 (18.0-109.0)

57.0 (30.0-86.0)

0.01

Gender, male (n (%))

50 (83.3)

30 (90.9)

0.31

Hospitalization prior to ICU admission (n (%))

41 (68.3)

23 (69.7)

0.89

Underlying disease(s) (n (%))

   

 Chronic renal failure

5 (8.5)

5 (15.1)

0.32

 Cardiac chronic disease

38 (64.4)

27 (81.8)

0.08

 Diabetes mellitus

19 (32.2)

10 (30.3)

0.99

 COPD

15 (25.0)

9 (27.3)

0.81

 Cirrhosis

1 (1.7)

1 (3.3)

0.67

 Immunosuppression

4 (6.8)

0 (0.0)

0.13

 Cancer

7 (11.9)

3 (9.1)

0.68

Nursing-home resident (n (%))

2 (3.3)

0 (0.0)

0.29

Main admission diagnosis

   

 Respiratory distress (n (%))

21 (35.0)

12 (36.3)

0.89

 Extrapulmonary sepsis (n (%))

19 (31.7)

14 (42.4)

0.30

 Neurologic failure (n (%))

6 (10.0)

4 (12.1)

0.75

 Abdominal surgery (n (%))

2 (3.3)

0 (0.0)

0.29

 Miscellaneous (n (%))

12 (20.0)

3 (9.1)

0.17

Nasogastric tube (Yes (%))

58 (96.7)

33 (100)

0.30

CPIS day-1

5.0 (2.0-9.0)

5.0 (3.0-8.0)

0.38

CPIS day-3

7.0 (5.0-11.0)

7.0 (5.0-10.0)

0.30

SOFA day-1

7.0 (4.0-15.0)

10.0 (5.0-16.0)

<0.01

SOFA day-3

7.0 (4.0-14.0)

8.0 (4.0-15.0)

0.08

Renal failure on admission (Yes (%))

30 (50.0)

20 (60.6)

0.33

Serum creatinine (VAP day-1)

90.0 (27.0-404.0)

137.0 (34.0-321.0)

0.02

Serum creatinine (VAP day-3)

84.0 (14.0-332.0)

111.0 (27.0-329.0)

0.20

Length of ICU stay until VAP (days)

10.0 (2.0-60.0)

10.0 (2.0-72.0)

0.90

Duration of MV until VAP (days)

12.0 (2.0-52.0)

7.0 (2.0-69.0)

0.44

Septic shock (VAP day-1) (n (%))

18 (30.5)

17 (51.5)

0.05

Late-onset VAP (≥5 days after MV onset) (n (%))

41 (68.3)

25 (75.8)

0.45

MDR bacteria (n (%))

19 (32.2)

14 (42.4)

0.33

Appropriate antibiotic therapy within the first 24-hour of VAP (n (%))

49 (83.0)

21 (65.6)

0.06

Steroids therapy during VAP period (n (%))

23 (39.6)

18 (54.5)

0.17

Statin continuation after ICU admission (n (%))

37 (61.7)

15 (45.4)

0.13

  1. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CPIS, clinical pulmonary infection score; SOFA, sequential organ failure assessment; MV, mechanical ventilation; MDR, multidrug resistant.
Back to article page

Critical Care

ISSN: 1364-8535